Biostratum, Inc.
Records under this name other than patents Biostratum, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,062,306 | Methods for identifying compounds for treating type 1 diabetes Formerly held In force · High confidence | In force | High confidence | |
| US 7,214,799 | Methods for the Synthesis of Pyridoxamine Formerly held Term ended Term ended Feb 9, 2025 · High confidence | Term ended | Term ended Feb 9, 2025 | High confidence |
| US 8,507,444 | ApoIII and the Treatment and Diagnosis of Diabetes Formerly held Term ended Term ended Feb 5, 2025 · High confidence | Term ended | Term ended Feb 5, 2025 | High confidence |
| US 8,030,288 | Methods for Identifying Compounds for the Treatment of Type 1 Diabetes Formerly held Term ended Term ended Jan 15, 2025 · High confidence | Term ended | Term ended Jan 15, 2025 | High confidence |
| US 8,084,439 | Methods for identifying compounds for the treatment of type 1 diabetes Formerly held Term ended Ended no later than Apr 29, 2024 · From the USPTO record | Term ended | Ended no later than Apr 29, 2024 | From the USPTO record |
| US 9,169,484 | Apoiii and the Treatment and Diagnosis of Diabetes Formerly held Term ended Term ended Apr 29, 2024 · High confidence | Term ended | Term ended Apr 29, 2024 | High confidence |
| US 10,060,935 | ApoIII and the Treatment and Diagnosis of Diabetes Formerly held Term ended Term ended Apr 29, 2024 · High confidence | Term ended | Term ended Apr 29, 2024 | High confidence |
| US 8,716,241 | ApoIII and the Treatment and Diagnosis of Diabetes Formerly held Lapsed on the fee record Ended May 6, 2022 · High confidence | Lapsed on the fee record | Ended May 6, 2022 | High confidence |
| US 8,431,712 | Methods for the Synthesis of Pyridoxamine Formerly held Lapsed on the fee record Ended Apr 30, 2021 · Medium confidence | Lapsed on the fee record | Ended Apr 30, 2021 | Medium confidence |
| US 6,638,907 | Laminin 8 and methods for its use Term ended Term ended Apr 28, 2020 · From the USPTO record | Term ended | Term ended Apr 28, 2020 | From the USPTO record |